A Novel Flavonoid Composition Targets Androgen Receptor Signaling and Inhibits Prostate Cancer Growth in Preclinical Models

Kenza Mamouni, Shumin Zhang, Xin Li, Yanhua Chen, Yang Yang, Jaeah Kim, Michael G. Bartlett, Ilsa M. Coleman, Peter S. Nelson, Omer Kucuk, Daqing Wu

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The high prevalence and long latency period of prostate cancer (PCa) provide a unique opportunity to control disease progression with dietary and nutraceutical approaches. We developed ProFine, a standardized composition of luteolin, quercetin, and kaempferol, and investigated its potential as a nutraceutical for PCa in preclinical models. The three ingredients of ProFine demonstrated synergistic in vitro cytotoxicity and effectively induced apoptosis in PCa cells. ProFine markedly affected the transcriptome of PCa cells, suppressed the expression of androgen receptor, and inhibited androgen-regulated genes. Oral administration of ProFine did not exhibit obvious toxicities in mice, and the three ingredients retained their individual pharmacokinetic and bioavailability profiles. Importantly, ProFine significantly retarded the growth of PCa xenografts in athymic nude mice and extended the survival of animals. This study provides preclinical evidence supporting the promise of ProFine as a safe, efficacious, and affordable intervention to control PCa progression and improve clinical outcomes.

Original languageEnglish (US)
Pages (from-to)789-799
Number of pages11
JournalNeoplasia (United States)
Volume20
Issue number8
DOIs
StatePublished - Aug 1 2018

Fingerprint

Androgen Receptors
Flavonoids
Prostatic Neoplasms
Growth
Dietary Supplements
Nude Mice
Luteolin
Quercetin
Transcriptome
Heterografts
Biological Availability
Androgens
Oral Administration
Disease Progression
Pharmacokinetics
Apoptosis
Genes

ASJC Scopus subject areas

  • Cancer Research

Cite this

A Novel Flavonoid Composition Targets Androgen Receptor Signaling and Inhibits Prostate Cancer Growth in Preclinical Models. / Mamouni, Kenza; Zhang, Shumin; Li, Xin; Chen, Yanhua; Yang, Yang; Kim, Jaeah; Bartlett, Michael G.; Coleman, Ilsa M.; Nelson, Peter S.; Kucuk, Omer; Wu, Daqing.

In: Neoplasia (United States), Vol. 20, No. 8, 01.08.2018, p. 789-799.

Research output: Contribution to journalArticle

Mamouni, K, Zhang, S, Li, X, Chen, Y, Yang, Y, Kim, J, Bartlett, MG, Coleman, IM, Nelson, PS, Kucuk, O & Wu, D 2018, 'A Novel Flavonoid Composition Targets Androgen Receptor Signaling and Inhibits Prostate Cancer Growth in Preclinical Models', Neoplasia (United States), vol. 20, no. 8, pp. 789-799. https://doi.org/10.1016/j.neo.2018.06.003
Mamouni, Kenza ; Zhang, Shumin ; Li, Xin ; Chen, Yanhua ; Yang, Yang ; Kim, Jaeah ; Bartlett, Michael G. ; Coleman, Ilsa M. ; Nelson, Peter S. ; Kucuk, Omer ; Wu, Daqing. / A Novel Flavonoid Composition Targets Androgen Receptor Signaling and Inhibits Prostate Cancer Growth in Preclinical Models. In: Neoplasia (United States). 2018 ; Vol. 20, No. 8. pp. 789-799.
@article{9876d80d466e4660b8cedbe0dfdd2bec,
title = "A Novel Flavonoid Composition Targets Androgen Receptor Signaling and Inhibits Prostate Cancer Growth in Preclinical Models",
abstract = "The high prevalence and long latency period of prostate cancer (PCa) provide a unique opportunity to control disease progression with dietary and nutraceutical approaches. We developed ProFine, a standardized composition of luteolin, quercetin, and kaempferol, and investigated its potential as a nutraceutical for PCa in preclinical models. The three ingredients of ProFine demonstrated synergistic in vitro cytotoxicity and effectively induced apoptosis in PCa cells. ProFine markedly affected the transcriptome of PCa cells, suppressed the expression of androgen receptor, and inhibited androgen-regulated genes. Oral administration of ProFine did not exhibit obvious toxicities in mice, and the three ingredients retained their individual pharmacokinetic and bioavailability profiles. Importantly, ProFine significantly retarded the growth of PCa xenografts in athymic nude mice and extended the survival of animals. This study provides preclinical evidence supporting the promise of ProFine as a safe, efficacious, and affordable intervention to control PCa progression and improve clinical outcomes.",
author = "Kenza Mamouni and Shumin Zhang and Xin Li and Yanhua Chen and Yang Yang and Jaeah Kim and Bartlett, {Michael G.} and Coleman, {Ilsa M.} and Nelson, {Peter S.} and Omer Kucuk and Daqing Wu",
year = "2018",
month = "8",
day = "1",
doi = "10.1016/j.neo.2018.06.003",
language = "English (US)",
volume = "20",
pages = "789--799",
journal = "Neoplasia (United States)",
issn = "1522-8002",
publisher = "Elsevier Inc.",
number = "8",

}

TY - JOUR

T1 - A Novel Flavonoid Composition Targets Androgen Receptor Signaling and Inhibits Prostate Cancer Growth in Preclinical Models

AU - Mamouni, Kenza

AU - Zhang, Shumin

AU - Li, Xin

AU - Chen, Yanhua

AU - Yang, Yang

AU - Kim, Jaeah

AU - Bartlett, Michael G.

AU - Coleman, Ilsa M.

AU - Nelson, Peter S.

AU - Kucuk, Omer

AU - Wu, Daqing

PY - 2018/8/1

Y1 - 2018/8/1

N2 - The high prevalence and long latency period of prostate cancer (PCa) provide a unique opportunity to control disease progression with dietary and nutraceutical approaches. We developed ProFine, a standardized composition of luteolin, quercetin, and kaempferol, and investigated its potential as a nutraceutical for PCa in preclinical models. The three ingredients of ProFine demonstrated synergistic in vitro cytotoxicity and effectively induced apoptosis in PCa cells. ProFine markedly affected the transcriptome of PCa cells, suppressed the expression of androgen receptor, and inhibited androgen-regulated genes. Oral administration of ProFine did not exhibit obvious toxicities in mice, and the three ingredients retained their individual pharmacokinetic and bioavailability profiles. Importantly, ProFine significantly retarded the growth of PCa xenografts in athymic nude mice and extended the survival of animals. This study provides preclinical evidence supporting the promise of ProFine as a safe, efficacious, and affordable intervention to control PCa progression and improve clinical outcomes.

AB - The high prevalence and long latency period of prostate cancer (PCa) provide a unique opportunity to control disease progression with dietary and nutraceutical approaches. We developed ProFine, a standardized composition of luteolin, quercetin, and kaempferol, and investigated its potential as a nutraceutical for PCa in preclinical models. The three ingredients of ProFine demonstrated synergistic in vitro cytotoxicity and effectively induced apoptosis in PCa cells. ProFine markedly affected the transcriptome of PCa cells, suppressed the expression of androgen receptor, and inhibited androgen-regulated genes. Oral administration of ProFine did not exhibit obvious toxicities in mice, and the three ingredients retained their individual pharmacokinetic and bioavailability profiles. Importantly, ProFine significantly retarded the growth of PCa xenografts in athymic nude mice and extended the survival of animals. This study provides preclinical evidence supporting the promise of ProFine as a safe, efficacious, and affordable intervention to control PCa progression and improve clinical outcomes.

UR - http://www.scopus.com/inward/record.url?scp=85049860330&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049860330&partnerID=8YFLogxK

U2 - 10.1016/j.neo.2018.06.003

DO - 10.1016/j.neo.2018.06.003

M3 - Article

C2 - 29981500

AN - SCOPUS:85049860330

VL - 20

SP - 789

EP - 799

JO - Neoplasia (United States)

JF - Neoplasia (United States)

SN - 1522-8002

IS - 8

ER -